What GLP-1 is
GLP-1 is the endogenous incretin hormone behind the modern GLP-1 drug category, influencing appetite, gastric emptying, and glucose-dependent insulin response.
GLP-1 is grouped under Fat Loss + GLP-1s / Endogenous / Biology on PeptideFactCheck because it is the foundation of the biggest current peptide category in mainstream medicine and weight-loss culture.
The useful starting point is to separate the molecule itself from the internet story around it. It is the foundation of the biggest current peptide category in mainstream medicine and weight-loss culture.
Why people keep looking it up
It is the foundation of the biggest current peptide category in mainstream medicine and weight-loss culture.
GLP-1 is the endogenous incretin hormone behind the modern GLP-1 drug category, influencing appetite, gastric emptying, and glucose-dependent insulin response.
GLP-1 tends to stay in the conversation because it touches a familiar public theme: incretin hormone, appetite signaling, and glucose control. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
High-confidence human biology with major clinical relevance.
The biology is well established in humans, but this entry is about the native peptide rather than every commercial analog.
Mechanistic support is extensive across incretin and metabolic physiology.
Why this page carries the current tier: High-confidence human biology with major clinical relevance.
The current seed trail for GLP-1 is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
Confusion usually comes from mixing endogenous GLP-1 biology with specific approved or counterfeit drug products.
This is an endogenous biology entry rather than a branded FDA-approved drug profile.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for GLP-1. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for GLP-1 is CID 16133831. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16133831
- Formula
- C149H226N40O45
- Molecular weight
- 3297.6
- InChIKey
- DTHNMHAUYICORS-KTKZVXAJSA-N
Matched synonyms include Glucagon Like Peptide 1, RefChem:922267, GLP 1, DTXCID901772398, DTXSID701343589, 89750-14-1, Glp-1, Glucagon-Like Peptide 1.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for GLP-1 returns 1954 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for GLP-1 returns 32302 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- XIMONTH GLP-1 Patches
- Generic names
- GLYCERIN
- Routes
- TOPICAL
- Application numbers
- M016
Indications and usage. Clean and dry your skin, apply the product to your upper arms, abdomen or thighs, press gently to ensure adhesion, leave it on for 6-8 hours and then remove.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.